دورية أكاديمية
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials
| العنوان: | Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials |
|---|---|
| المؤلفون: | Terrisse, Safae, Karamouza, Eleni, Parker, Chris C, Sartor, Oliver, James, Nicholas D, Pirrie, Sarah, Collette, Laurence, Tombal, Bertrand, Chahoud, Jad, Smeland, Sigbjorn, Erikstein, Bjorn, Pignon, Jean-Pierre, Fizazi, Karim, Le Teuff, Gwénaël, for the MORPHEP Collaborative Group |
| المساهمون: | UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie |
| المصدر: | JAMA Oncology, Vol. 6, no. 2, p. 206-216 (2020) |
| بيانات النشر: | American Medical Association |
| سنة النشر: | 2020 |
| المجموعة: | DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| الوصف: | IMPORTANCE Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has demonstrated an overall survival (OS) benefit from an α-emitting RI, radium 223 (223Ra), vs standard of care. Yet no head-to-head comparison has been done between α-emitting and β-emitting RIs. OBJECTIVE To assess OS in men with bone metastases from CRPC treated with bone-targeted RIs and to compare the effects of α-emitting RIs with β-emitting RIs. DATA SOURCES PubMed, Cochrane Library, ClinicalTrials.gov, and meeting proceedings between January 1993 and June 2013 were reviewed. Key terms included randomized trials, radioisotopes, radiopharmaceuticals, and prostate cancer. Data were collected, checked, and analyzed from February 2017 to October 2018. STUDY SELECTION Selected trials included patients with prostate cancer, recruited more than 50 patients from January 1993 to June 2013, compared RI use with no RI use (placebo, external radiotherapy, or chemotherapy), and were randomized. Patients were diagnosed with histologically proven prostate cancer and disease progression after both surgical or chemical castration and have evidence of bone metastasis. Nine randomized clinical trials were identified as eligible, but 3 were excluded for insufficient data. DATA EXTRACTION AND SYNTHESIS Individual patient datawere requested for each eligible trial, and all data were checked with a standard procedure. The log-rank test stratified by trial was used to estimate hazard ratios (HRs), and a similar fixed-effects (FE) model was used to estimate odds ratios (ORs). The between-trial heterogeneity of treatment effects was evaluated by Cochran test and I2 and was accounted by a random-effects (RE) model. MAIN OUTCOMES AND MEASURES Overall survival; secondary outcomeswere symptomatic skeletal event (SSE)–free survival and adverse events. RESULTS Based on 6 randomized clinical trials including 2081 ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2374-2437 2374-2445 |
| العلاقة: | info:eu-repo/grantAgreement/Bayer//; info:eu-repo/grantAgreement/Ligue Nationale Contre le Cancer//; boreal:223808; http://hdl.handle.net/2078.1/223808Test; info:pmid/; urn:ISSN:2374-2437; urn:EISSN:2374-2445 |
| DOI: | 10.1001/jamaoncol.2019.4097 |
| الإتاحة: | https://doi.org/10.1001/jamaoncol.2019.4097Test http://hdl.handle.net/2078.1/223808Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.27814F1A |
| قاعدة البيانات: | BASE |
| تدمد: | 23742437 23742445 |
|---|---|
| DOI: | 10.1001/jamaoncol.2019.4097 |